Type 2 diabetes (T2D) is one of the biggest health challenges in China, where the prevalence of disease is globally the highest. Traditional therapies such as biguanides, insulin secretagogues (sulfonylureas and glinides), and alpha-glucosidase inhibitors have enjoyed high patient uptake in China due to their long market presence, physician comfort prescribing them, and favorable reimbursement. The T2D-therapy market in China will expand over the 2018-2028 forecast period, fueled by the disease’s increasing prevalence and the uptake of novel agents, particularly Johnson & Johnson’s Invokana and Sanofi’s Lyxumia. These drugs offer efficacy in lowering cardiovascular risk and eliciting weight loss, respectively, and are expected to be included in China’s NRDL. Nevertheless, despite the availability of many traditional and novel T2D agents, cost-effective therapies are still needed to improve the disease control rate, representing an opportunity for new drug developers. Additionally, with the ongoing reforms in China’s regulatory and access and reimbursement landscape, multinational companies are likely to be increasingly encouraged to enter the T2D-therapy market.


  • How large is China’s drug-treatable T2D population, and how will the drug-treatment rate change during the forecast period?
  • Which are the most commercially relevant drugs in China’s T2D market and why? What are interviewed experts’ insights into current treatment options? Which clinical needs remain unfulfilled?
  • What are the market access considerations for key therapies in the T2D pipeline in China? What sales/uptake could they secure in T2D? What are interviewed experts’ opinions of key emerging therapies?
  • What are the key drivers and constraints in the Chinese T2Dtherapymarket, and how will the market evolve over the forecast period?


China In-Depth: Comprehensive market intelligence providing world-class epidemiology, keen insight into the China-specific access and reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary market research.

Release Date

October 2019



Primary Research

Qualitative and quantitative insights based on five country-specific interviews with thought-leading endocrinologists and supported by survey data collected for this and other DRG research.


Diagnosed prevalence of T2D with urban and rural breakup. Clinically relevant and market-relevant drug-treatable populations.


Ten-year, annualized, drug-level sales and patient shares of key T2D therapies through 2028, based on primary and secondary market research to formulate bottom-up assumptions.

Emerging Therapies

Phase III/PR: 24 agents; Phase II: 6 agents; coverage of select early-phase products.

Table of contents

  • Type 2 Diabetes - Geographic Focus: China - Type 2 Diabetes | China In-Depth | China
    • China In-Depth: Type 2 Diabetes

Author(s): Karan Verma, MSc; Joseph Granato, MPH; Akash Saini, Ph.D.

Karan is a Senior Analyst with the China-in-Depth team at Decision Resources Group, where he specializes in disease landscape and forecast reports based on a range of indications and therapy areas and focused specifically on the China healthcare market.

Before joining DRG, Karan was associated with Aranca, a boutique management consulting firm. Prior to that, he was working with Frost & Sullivan, a global healthcare consulting firm, where he was helping clients devise market entry strategies, conducting technology feasibility studies, and doing competitive intelligence for new product development. His prior experience also includes a short KTP program with the University of Southampton, UK. Karan has earned his MSc in Biomedical Engineering from the University of Warwick, and B.E. in Biomedical Engineering from Maharshi Dayanand University, Haryana, India.


Joseph Granato joined Decision Resources Group in 2012 and previously worked on both Market Access and Global Market Access products.  Joseph is currently responsible for forecasting the prevalence and incidence of disease populations throughout the world.  He is also tasked with identifying at risk populations and developing new epidemiological methods used to predict overall population health.

He received his M.P.H. from Des Moines University where he worked on several population health projects including the delivery of continuing medical education on tick-borne diseases.  He also holds a B.S. in Animal Science from the University of Tennessee.  Prior to his time with DRG Joseph worked with the Monroe County Health Department on the surveillance of reportable diseases including Dengue Fever.

Akash is a manager on the China In-Depth team at Decision Resources Group. Since 2016, he has specialized in market research and competitive intelligence in a range of diseases in diverse therapeutic areas, including gastric cancer, non-small-cell lung cancer (NSCLC), and rheumatoid arthritis. He has authored various research and analysis reports for the U.S., EU5, and China markets, leveraging primary and secondary market research and real-world evidence.

Prior to joining DRG, Akash was a postdoctoral fellow at the University of Massachusetts Medical School. He holds a Ph.D. from the International Centre for Genetic Engineering and Biotechnology in New Delhi and an M.Sc. from Jawaharlal Nehru University in New Delhi.

Related Reports

Type 2 Diabetes - Landscape & Forecast - Disease Landscape & Forecast

View Details

Type 2 Diabetes | Disease Landscape and Forecast | G7 | 2020

The type 2 diabetes therapy market will steadily expand over the 2019-2029 study period, fueled by increasing prevalence and high unmet need for drugs that can effectively control the disease in th...

View Details

Type 2 Diabetes - Epidemiology - Extrapolated Worldwide Coverage

DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key type 2 diabetes patient...

View Details

Type 2 Diabetes - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US) Dashboard

Metformin and sulfonylureas are the most heavily prescribed type 2 diabetes drugs and dominate the early lines of therapy, before disease progression requires insulin replacement. The emergence of...

View Details